New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Subscribe To Our Newsletter & Stay Updated
